Lista de obras -

18F-FDG PET/CT for monitoring induction chemotherapy in patients with primary inoperable penile carcinoma: first clinical results

artículo científico publicado en 2010

A prospective observational registry evaluating clinical outcomes of Radium-223 treatment in a nonstudy population

artículo científico publicado en 2019

Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations

artículo científico publicado en 2020

Age-Associated Hematological Toxicity in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Docetaxel in Clinical Practice

artículo científico publicado en 2019

An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer

artículo científico publicado en 2021

Androgen modulation of XBP1 is functionally driving part of the AR transcriptional program

scientific article published on 01 February 2020

Androgen receptor DNA binding and chromatin accessibility profiling in prostate cancer.

artículo científico publicado en 2015

Androgen receptor enhancer usage and the chromatin regulatory landscape in human prostate cancers

artículo científico publicado en 2019

Androgen receptor profiling predicts prostate cancer outcome

artículo científico publicado en 2015

Androgen receptor reprogramming demarcates prognostic, context-dependent gene sets in primary and metastatic prostate cancer

artículo científico publicado en 2022

Androgen receptor signalling in macrophages promotes TREM-1-mediated prostate cancer cell line migration and invasion

scientific article published on 09 September 2020

Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models.

artículo científico publicado en 2010

Assessment of Simplified Methods for Quantification of 18F-FDHT Uptake in Patients with Metastatic Castration-Resistant Prostate Cancer

artículo científico publicado en 2019

CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate Tumorigenesis

scientific article published on 01 May 2019

CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate Tumorigenesis

artículo científico publicado en 2019

Cabazitaxel in patients with metastatic castration-resistant prostate cancer: results of a compassionate use program in the Netherlands.

artículo científico publicado en 2013

Carboplatin based induction chemotherapy for nonorgan confined bladder cancer--a reasonable alternative for cisplatin unfit patients?

artículo científico publicado en 2012

Cistrome Partitioning Reveals Convergence of Somatic Mutations and Risk Variants on Master Transcription Regulators in Primary Prostate Tumors

artículo científico publicado en 2019

Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment.

artículo científico publicado en 2013

Concomitant intake of abiraterone acetate and food to increase pharmacokinetic exposure: real life data from a therapeutic drug monitoring programme

artículo científico publicado en 2020

Concurrent radiotherapy and panitumumab after lymph node dissection and induction chemotherapy for invasive bladder cancer

artículo científico publicado en 2019

Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial

artículo científico publicado en 2017

Determinants of resistance to 2',2'-difluorodeoxycytidine (gemcitabine).

artículo científico publicado en 2002

Drug-Induced Epigenomic Plasticity Reprograms Circadian Rhythm Regulation to Drive Prostate Cancer toward Androgen Independence

artículo científico publicado en 2022

Effect of dexamethasone on the antileukemic effect of cytarabine: role of deoxycytidine kinase

artículo científico publicado en 2020

Effects of Budesonide on Cabazitaxel Pharmacokinetics and Cabazitaxel-Induced Diarrhea: A Randomized, Open-Label Multicenter Phase II Study

artículo científico publicado en 2016

Enzalutamide as a Fourth- or Fifth-Line Treatment Option for Metastatic Castration-Resistant Prostate Cancer

artículo científico publicado en 2016

Enzalutamide therapy for advanced prostate cancer: efficacy, resistance and beyond

artículo científico publicado en 2018

Exposure to Docetaxel in the Elderly Patient Population: a Population Pharmacokinetic Study

scientific article published on 15 November 2019

Exposure-Response Assessment of Enzalutamide and Its Major Metabolites in a Real-World Cohort of Patients with Metastatic Castration-Resistant Prostate Cancer

artículo científico publicado en 2019

Expression microarray analysis and oligo array comparative genomic hybridization of acquired gemcitabine resistance in mouse colon reveals selection for chromosomal aberrations

artículo científico publicado en 2005

Extensive androgen receptor enhancer heterogeneity in primary prostate cancers underlies transcriptional diversity and metastatic potential

scientific article published in 2022

Frequent clonal relations between metastases and non-index prostate cancer lesions

article

Functional mapping of androgen receptor enhancer activity

artículo científico publicado en 2021

Genetic Aspects and Molecular Testing in Prostate Cancer: A Report from a Dutch Multidisciplinary Consensus Meeting

artículo científico publicado en 2023

HLA class II expression on tumor cells and low numbers of tumor-associated macrophages predict clinical outcome in oropharyngeal cancer.

artículo científico publicado en 2018

Impact of age on exposure to oral antiandrogen therapies in clinical practice

artículo científico publicado en 2018

In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant

artículo científico publicado en 2005

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

artículo científico publicado en 2014

Loss of androgen receptor signaling in prostate cancer-associated fibroblasts (CAFs) promotes CCL2- and CXCL8-mediated cancer cell migration.

artículo científico publicado en 2018

Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial

scientific article published on 14 September 2020

Neoadjuvant induction dose-dense MVAC for muscle invasive bladder cancer: efficacy and safety compared with classic MVAC and gemcitabine/cisplatin

artículo científico publicado en 2015

Neoadjuvant taxane-based combination chemotherapy in patients with advanced penile cancer

artículo científico publicado en 2014

Occult lymph node metastases in patients with carcinoma invading bladder muscle: incidence after neoadjuvant chemotherapy and cystectomy vs after cystectomy alone

artículo científico publicado en 2014

Opposing transcriptional programs of KLF5 and AR emerge during therapy for advanced prostate cancer

artículo científico publicado en 2021

Optimized ChIP-seq method facilitates transcription factor profiling in human tumors

scientific article published on 28 December 2018

Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1.

artículo científico publicado en 2016

Prognostic parameters for response to enzalutamide after docetaxel and abiraterone treatment in metastatic castration-resistant prostate cancer patients; a possible time relation

artículo científico publicado en 2015

Prostate cancer reactivates developmental epigenomic programs during metastatic progression

artículo científico publicado en 2020

Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer

artículo científico publicado en 2020

Reduced NCOR2 expression accelerates androgen deprivation therapy failure in prostate cancer

artículo científico publicado en 2021

Staurosporine increases toxicity of gemcitabine in non-small cell lung cancer cells: role of protein kinase C, deoxycytidine kinase and ribonucleotide reductase

artículo científico publicado en 2010

Survival Outcomes From a Cumulative Analysis of Worldwide Observational Studies on Sequential Use of New Agents in Metastatic Castration-Resistant Prostate Cancer

scientific article published on 27 September 2019

TLE3 loss confers AR inhibitor resistance by facilitating GR-mediated human prostate cancer cell growth

artículo científico publicado en 2019

The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate Cancer

artículo científico publicado en 2017

The adaptive immune system promotes initiation of prostate carcinogenesis in a human c-Myc transgenic mouse model.

artículo científico publicado en 2017

The circadian cryptochrome, CRY1, is a pro-tumorigenic factor that rhythmically modulates DNA repair

artículo científico publicado en 2021

The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact

artículo científico publicado en 2019

The intravenous to oral switch of taxanes: strategies and current clinical developments

artículo científico publicado en 2020

Third-line Life-prolonging Drug Treatment in a Real-world Metastatic Castration-resistant Prostate Cancer Population: Results from the Dutch Castration-resistant Prostate Cancer Registry

artículo científico publicado en 2020

mTOR pathway activation is a favorable prognostic factor in human prostate adenocarcinoma.

artículo científico publicado en 2016

Lista de obras de

18F-FDG PET/CT for monitoring induction chemotherapy in patients with primary inoperable penile carcinoma: first clinical results

A prospective observational registry evaluating clinical outcomes of Radium-223 treatment in a nonstudy population

Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations

Age-Associated Hematological Toxicity in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Docetaxel in Clinical Practice

An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer

Androgen modulation of XBP1 is functionally driving part of the AR transcriptional program

Androgen receptor DNA binding and chromatin accessibility profiling in prostate cancer.

Androgen receptor enhancer usage and the chromatin regulatory landscape in human prostate cancers

Androgen receptor profiling predicts prostate cancer outcome

Androgen receptor reprogramming demarcates prognostic, context-dependent gene sets in primary and metastatic prostate cancer

Androgen receptor signalling in macrophages promotes TREM-1-mediated prostate cancer cell line migration and invasion

Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models.

Assessment of Simplified Methods for Quantification of 18F-FDHT Uptake in Patients with Metastatic Castration-Resistant Prostate Cancer

CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate Tumorigenesis

CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate Tumorigenesis

Cabazitaxel in patients with metastatic castration-resistant prostate cancer: results of a compassionate use program in the Netherlands.

Carboplatin based induction chemotherapy for nonorgan confined bladder cancer--a reasonable alternative for cisplatin unfit patients?

Cistrome Partitioning Reveals Convergence of Somatic Mutations and Risk Variants on Master Transcription Regulators in Primary Prostate Tumors

Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment.

Concomitant intake of abiraterone acetate and food to increase pharmacokinetic exposure: real life data from a therapeutic drug monitoring programme

Concurrent radiotherapy and panitumumab after lymph node dissection and induction chemotherapy for invasive bladder cancer

Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial

Determinants of resistance to 2',2'-difluorodeoxycytidine (gemcitabine).

Drug-Induced Epigenomic Plasticity Reprograms Circadian Rhythm Regulation to Drive Prostate Cancer toward Androgen Independence

Effect of dexamethasone on the antileukemic effect of cytarabine: role of deoxycytidine kinase

Effects of Budesonide on Cabazitaxel Pharmacokinetics and Cabazitaxel-Induced Diarrhea: A Randomized, Open-Label Multicenter Phase II Study

Enzalutamide as a Fourth- or Fifth-Line Treatment Option for Metastatic Castration-Resistant Prostate Cancer

Enzalutamide therapy for advanced prostate cancer: efficacy, resistance and beyond

Exposure to Docetaxel in the Elderly Patient Population: a Population Pharmacokinetic Study

Exposure-Response Assessment of Enzalutamide and Its Major Metabolites in a Real-World Cohort of Patients with Metastatic Castration-Resistant Prostate Cancer

Expression microarray analysis and oligo array comparative genomic hybridization of acquired gemcitabine resistance in mouse colon reveals selection for chromosomal aberrations

Extensive androgen receptor enhancer heterogeneity in primary prostate cancers underlies transcriptional diversity and metastatic potential

Frequent clonal relations between metastases and non-index prostate cancer lesions

Functional mapping of androgen receptor enhancer activity

Genetic Aspects and Molecular Testing in Prostate Cancer: A Report from a Dutch Multidisciplinary Consensus Meeting

HLA class II expression on tumor cells and low numbers of tumor-associated macrophages predict clinical outcome in oropharyngeal cancer.

Impact of age on exposure to oral antiandrogen therapies in clinical practice

In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

Loss of androgen receptor signaling in prostate cancer-associated fibroblasts (CAFs) promotes CCL2- and CXCL8-mediated cancer cell migration.

Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial

Neoadjuvant induction dose-dense MVAC for muscle invasive bladder cancer: efficacy and safety compared with classic MVAC and gemcitabine/cisplatin

Neoadjuvant taxane-based combination chemotherapy in patients with advanced penile cancer

Occult lymph node metastases in patients with carcinoma invading bladder muscle: incidence after neoadjuvant chemotherapy and cystectomy vs after cystectomy alone

Opposing transcriptional programs of KLF5 and AR emerge during therapy for advanced prostate cancer

Optimized ChIP-seq method facilitates transcription factor profiling in human tumors

Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1.

Prognostic parameters for response to enzalutamide after docetaxel and abiraterone treatment in metastatic castration-resistant prostate cancer patients; a possible time relation

Prostate cancer reactivates developmental epigenomic programs during metastatic progression

Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer

Reduced NCOR2 expression accelerates androgen deprivation therapy failure in prostate cancer

Staurosporine increases toxicity of gemcitabine in non-small cell lung cancer cells: role of protein kinase C, deoxycytidine kinase and ribonucleotide reductase

Survival Outcomes From a Cumulative Analysis of Worldwide Observational Studies on Sequential Use of New Agents in Metastatic Castration-Resistant Prostate Cancer

TLE3 loss confers AR inhibitor resistance by facilitating GR-mediated human prostate cancer cell growth

The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate Cancer

The adaptive immune system promotes initiation of prostate carcinogenesis in a human c-Myc transgenic mouse model.

The circadian cryptochrome, CRY1, is a pro-tumorigenic factor that rhythmically modulates DNA repair

The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact

The intravenous to oral switch of taxanes: strategies and current clinical developments

Third-line Life-prolonging Drug Treatment in a Real-world Metastatic Castration-resistant Prostate Cancer Population: Results from the Dutch Castration-resistant Prostate Cancer Registry

mTOR pathway activation is a favorable prognostic factor in human prostate adenocarcinoma.